Regulatory Aspects of Post-Approval Safety Reporting for Generic Drug Products in the US

By  

Applied Clinical Research, Clinical Trials and Regulatory Affairs, Vol. 3, Iss. 3, 2016-12 ,pp. : 142-150

Bentham Science Publishers

Access to resources Recommend Favorite

Belimumab Efficacy is `Mild' but Market Potential Still Great†: Anticipating US Approval of the First Lupus Drug Since 1957

By Weintraub Ben  

BioDrugs, Vol. 25, Iss. 3, 2011-06 ,pp. : 203-205

Adis International

Access to resources Recommend Favorite

US Biosimilar Pathway Unlikely to be Used†: Developers Will Opt for a Traditional BLA Filing

By Wiatr Claudia  

BioDrugs, Vol. 25, Iss. 1, 2011-02 ,pp. : 63-67

Adis International

Access to resources Recommend Favorite

Regulatory Overview of Biosimilars: Current Scenario and Future Opportunities

By  

Applied Clinical Research, Clinical Trials and Regulatory Affairs, Vol. 2, Iss. 3, 2016-02 ,pp. : 158-164

Bentham Science Publishers

Access to resources Recommend Favorite

Managing and Responding to FDA Inspections

By  

Applied Clinical Research, Clinical Trials and Regulatory Affairs, Vol. 2, Iss. 1, 2015-10 ,pp. : 33-36

Bentham Science Publishers

Access to resources Recommend Favorite